Investigation of the outpatient chemotherapy for lung cancer patients in Tokushima University Hospital

DOI IR Web Site PubMed 1 Citations 17 References Open Access
  • Goto Hisatsugu
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
  • Hanibuchi Masaki
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
  • Sakaguchi Satoshi
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
  • Kanematsu Takanori
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
  • Kakiuchi Soji
    Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Graduate School
  • Tomimoto Hideki
    Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Graduate School
  • Azuma Masahiko
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
  • Tezuka Toshifumi
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School
  • Tada Hiroya
    Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Graduate School
  • Miki Yukiyo
    Outpatient Chemotherapy Unit, Tokushima University Hospital
  • Nakamura Toshimi
    Outpatient Chemotherapy Unit, Tokushima University Hospital
  • Sone Saburo
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School Department of Medical Oncology, Institute of Health Biosciences, the University of Tokushima Graduate School
  • Nishioka Yasuhiko
    Department of Respiratory Medicine and Rheumatology, Institute of Health Biosciences, the University of Tokushima Graduate School

Search this article

Description

Platinum-doublet regimens and docetaxel as first- and second-line chemotherapy, respectively, are shown to prolong the survival of lung cancer patients in various randomized phase III studies. However, the evidence for the efficacy of chemotherapy for lung cancer in the clinical practice is still insufficient. In the present study, we investigated the effectiveness and safety of outpatient chemotherapy for lung cancer in the clinical practice. Ninety-four lung cancer cases were retrospectively analyzed. Among these cases, 67 (71.3%) were non-small cell lung cancer (NSCLC) and 27 (28.7%) were small cell lung cancer (SCLC). The response rates in SCLC and NSCLC patients were 55.6% (15/27) and 16.9% (11/65), respectively. Objective tumor response rates for the patients were found to decrease substantially with each line of treatment as described previously. All adverse events were well tolerated and no treatment-related death was observed. Median time to treatment failures (TTFs) of first-line treatment were 10.1 months and 4.8 months in SCLC and NSCLC, respectively. These findings indicate that even in the setting of clinical practice, the efficacy and safety of chemotherapy is strictly insured by the appropriate therapeutic management. J. Med. Invest. 58: 219-226, August, 2011

Journal

Citations (1)*help

See more

References(17)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top